Cameron Health

Cameron Health was a medical-device company based in San Clemente, California, that developed a subcutaneous implantable cardioverter-defibrillator (S-ICD). Its principal innovation was to treat patients at risk of life-threatening ventricular arrhythmias without placing a lead through the veins and into the heart. Instead, the system positioned the defibrillator outside the rib cage and used a subcutaneous electrode to sense cardiac activity and deliver a therapeutic shock from outside the heart. The company addressed an important weakness in conventional transvenous implantable cardioverter-defibrillators. Traditional ICDs use leads threaded through the venous system into the heart. Those leads can complicate implantation and may fail over time, while lead extraction or replacement can present additional clinical risks. Cameron Health's approach sought to separate the life-saving defibrillation function from the need for an intracardiac lead, making implantation less invasive and potentially useful for patients with limited venous access, elevated infection risk, or conditions that made transvenous systems less suitable. The trade-off was that the S-ICD was bulkier than many conventional ICDs and could not provide pacing functions. Consequently, it was not intended for every patient who might otherwise receive a combined pacemaker and defibrillator. Its target population was primarily patients requiring defibrillation but not ongoing bradycardia pacing or antitachycardia pacing. Cameron Health's development program progressed through early feasibility work and multicenter clinical evaluation. A 53-patient experience was reported at the European Society of Cardiology Congress in 2005. A later study involving 55 patients at 10 centers in Europe and New Zealand was conducted in 2008 and 2009. The reported results showed successful conversion of induced ventricular fibrillation in nearly all tested episodes and supported the device's submission to European authorities. The system subsequently received European marketing approval. A larger United States study was undertaken as part of the effort to secure US regulatory approval. Boston Scientific established a relationship with Cameron Health in 2004 by obtaining an exclusive purchase option and making an equity investment. Cameron Health later raised slightly more than $50 million in additional financing in 2008 from a group of healthcare investors organized by Piper Jaffray, including PTV Healthcare Capital, Delphi Ventures, Sorrento Ventures, Three Arch Partners, and Versant Ventures. In June 2012, Boston Scientific completed its acquisition of Cameron Health. The transaction was valued at up to approximately $1.3 billion, with consideration paid incrementally as revenue milestones were achieved. Following the acquisition, Cameron Health ceased to operate as an independent company, while its S-ICD technology became part of Boston Scientific's cardiac-rhythm-management portfolio. Boston Scientific continued marketing the S-ICD system, extending the commercial life of the technology under its own corporate ownership. Cameron Health is therefore best understood as an acquired medical-technology company whose main historical significance lies in helping establish the entirely subcutaneous defibrillator as an alternative to transvenous ICD systems.

Cameron Health developed in the field of cardiac rhythm management, concentrating on a way to deliver implantable defibrillation without placing a lead inside the heart. Conventional implantable cardioverter-defibrillators generally rely on transvenous leads inserted through the venous system and positioned in the heart. Cameron Health's proposed alternative placed the pulse generator outside the thoracic wall and used a subcutaneous electrode, allowing the system to detect dangerous rhythms and deliver a shock without an intracardiac connection. The concept was designed around the clinical risks and complexity associated with transvenous systems. Intracardiac leads can be difficult to implant and may become a long-term point of failure. Lead malfunction can result in inappropriate shocks or loss of therapy, while lead revision and extraction can expose patients to additional procedural risk. Cameron Health therefore presented the S-ICD as a less invasive option for selected patients, particularly those who needed protection from sudden cardiac death but did not require the pacing capabilities of a conventional pacemaker-defibrillator combination. Early clinical work established feasibility. A 53-patient experience was reported in 2005 at the European Society of Cardiology Congress. Cameron Health then conducted a second study in 2008 and 2009 involving 55 patients at 10 centers in Europe and New Zealand. In the reported testing, 53 patients experienced two episodes of induced fibrillation, and 52 of those patients had both episodes successfully converted. Follow-up covered 46 patient-years; 54 of the 55 patients remained alive, with the reported death attributed to renal failure. The system also treated spontaneous sustained ventricular tachyarrhythmias in the small study population, including repeated episodes in one patient. The clinical findings were submitted to European regulatory authorities in 2009 and contributed to European marketing approval. The company also pursued a larger, approximately 300-patient US study intended to support approval in the United States. The development program positioned Cameron Health as an important early commercial developer of a fully subcutaneous ICD rather than merely a supplier of conventional transvenous components. Cameron Health's financing and corporate development were closely connected to Boston Scientific. In 2004, Boston Scientific acquired an exclusive option to purchase the company and made an undisclosed equity investment. In 2008, additional investors supplied slightly more than $50 million through a financing organized by Piper Jaffray. The participating firms included PTV Healthcare Capital, Delphi Ventures, Sorrento Ventures, Three Arch Partners, and Versant Ventures. Boston Scientific completed its acquisition of Cameron Health in June 2012. The consideration was reported at approximately $1.3 billion in total, paid incrementally as revenue milestones were reached. The purchase ended Cameron Health's independent corporate existence but transferred its technology and product platform into Boston Scientific's cardiac-device business. Cameron Health also had a European office, Cameron Health BV, in Arnhem, the Netherlands. The S-ICD's principal limitations remained part of its clinical positioning. The system was larger than many traditional ICDs and did not provide pacing, narrowing the group of patients for whom it was appropriate. Nevertheless, its leadless-in-the-heart architecture offered an alternative for patients in whom avoiding transvenous access was clinically valuable. Under Boston Scientific, the S-ICD platform continued to be marketed, making Cameron Health's main legacy the development and commercialization of a new category of implantable defibrillation technology.

• 2012

  Acquired by Boston Scientific

  [1]Cameron Healthen.wikipedia.org

  Boston Scientific completed its acquisition of Cameron Health in a transaction valued at approximately $1.3 billion, with payments linked to revenue milestones.

• 2010

  Early feasibility findings published

  [1]Cameron Healthen.wikipedia.org

  Updated and combined early-phase studies were published, reporting successful detection and conversion of induced ventricular fibrillation during electrophysiological testing.

• 2009

  European marketing approval supported

  [1]Cameron Healthen.wikipedia.org

  Clinical results from the European and New Zealand study were submitted to European authorities and resulted in approval to market the S-ICD system.

• 2008

  Multicenter study begins and new financing is secured

  [1]Cameron Healthen.wikipedia.org

  A 55-patient study was conducted across 10 centers in Europe and New Zealand, while Cameron Health obtained slightly more than $50 million in additional financing from healthcare investors.

• 2005

  Early S-ICD clinical experience reported

  [1]Cameron Healthen.wikipedia.org

  Results from a 53-patient experience with temporarily implanted subcutaneous defibrillators were reported at the European Society of Cardiology Congress.

• 2004

  Boston Scientific obtains an exclusive purchase option

  [1]Cameron Healthen.wikipedia.org

  Boston Scientific established a strategic relationship with Cameron Health by obtaining an exclusive option to acquire the company and making an undisclosed equity investment.

A medical-technology innovator focused on less invasive defibrillation by eliminating the need for transvenous leads inside the heart.

• Implantable cardioverter-defibrillator

  S-ICD System

  Cameron Health's principal product was a subcutaneous implantable cardioverter-defibrillator designed to detect dangerous ventricular arrhythmias and deliver a therapeutic electrical shock without a lead placed inside the heart. The pulse generator was implanted outside the rib cage and connected to a subcutaneous electrode. The system was intended for selected patients who required defibrillation but did not need the pacing functions available in many transvenous ICD systems. Its advantages included avoiding venous access and intracardiac leads; its limitations included a larger device profile and the absence of pacing capability.

• 2012

  Accept acquisition by Boston ScientificM&A

  Background

  Boston Scientific had held an exclusive purchase option and had invested in Cameron Health while the S-ICD platform progressed through clinical and regulatory development.

  Action taken

  Boston Scientific acquired Cameron Health, with total consideration of approximately $1.3 billion paid incrementally as revenue milestones were achieved.

  Aftermath

  Cameron Health no longer operated independently, and its S-ICD technology became part of Boston Scientific's cardiac-device portfolio.

  Total acquisition consideration. $1.3 billion (June 2012; paid incrementally as revenue milestones were achieved)

  Source

• 2004

  Pursue a fully subcutaneous defibrillation architectureStrategy

  Background

  Conventional ICDs used transvenous leads connected to the heart, creating implantation complexity and potential long-term lead-related complications.

  Action taken

  Cameron Health developed an ICD positioned outside the thoracic wall with a subcutaneous electrode rather than an intracardiac lead.

  Aftermath

  The approach led to clinical trials, European marketing approval, and eventual acquisition of the company by Boston Scientific.

  Source

1. 1Cameron Healthen.wikipedia.org